Variantyx, a Framingham, Mass.-based technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, secured $41.5M in series C-2 funding.
The round was led by New Era Capital Partners with participation from Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech.
The company intends to use the funds to accelerate growth and launch newly developed solutions across all markets, with a focus on precision oncology.
Led by Haim Neerman, CEO, Variantyx is a technology-driven precision medicine company providing solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians and patients to understand a person’s genetic makeup, leading to improved diagnostic capabilities and improved personalized treatment recommendations.
FinSMEs
14/02/2022